Acurx Pharmaceuticals LLC (ACXP) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.38 (-0.72%), Market cap $0.01B, 52-week low–high $0.29 ~ $8.10.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 a
Financial statements, price targets, institutional (13F) holdings and related news for Acurx Pharmaceuticals LLC are updated in real time on BlackAll Trade.
Acurx Pharmaceuticals LLC trades at $1.38 (-0.72%). Real-time quotes and charts are available on BlackAll Trade.
Acurx Pharmaceuticals LLC has a market cap of about $0.01B.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolsta